Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORTICO Phase IIb trial of vafidemstat in adult borderline personality disorder
2020-003469-20Phase 2Completed
- Sponsor
- Oryzon Genomics
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in borderline personality disorder (BPD) comparing Vafidemstat with Placebo (2 arms). Primary endpoint: Primary efficacy. Started Nov 2020; status: completed.
02
Drugs
vafidemstat
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on 2020-003469-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003469-20.